

Opinion Read the Latest

- THE JAN 6 HEARING REVOLT OF THE UNWOKE THE FUTURE OF THE NAVY HOW TO BE AN ANTICAPITALIST REASSURING DELTA VARIANT DATA BIDEN'S NEW DEATH TAX

OPINION | COMMENTARY

Why Is the FDA Attacking a Safe, Effective Drug?

Ivermectin is a promising Covid treatment and prophylaxis, but the agency is denigrating it.

By David R. Henderson and Charles L. Hooper July 28, 2021 12:34 pm ET

PRINT TEXT 1,155



Ivermectin in Buenos Aires, Jan. 26. PHOTO: ROBERTO ALMEIDA AVELEDO/ZUMA PRESS

Listen to article (5 minutes)

The Food and Drug Administration claims to follow the science. So why is it attacking ivermectin, a medication it certified in 1996?

Earlier this year the agency put out a special warning that "you should not use ivermectin to treat or prevent COVID-19." The FDA's statement included words and phrases such as "serious harm," "hospitalized," "dangerous," "very dangerous," "seizures," "coma and even death" and "highly toxic." Any reader would think the FDA was warning against poison pills. In fact, the drug is FDA-approved as a safe and effective antiparasitic.

LETTER TO THE EDITOR

- Writers Missed Ivermectin Study Retraction

Ivermectin was developed and marketed by Merck & Co. while one of us (Mr. Hooper) worked there years ago. William C. Campbell and Satoshi Omura won the 2015 Nobel Prize for Physiology or

Medicine for discovering and developing avermectin, which Mr. Campbell and associates modified to create ivermectin.

Ivermectin is on the World Health Organization's List of Essential Medicines. Merck has donated four billion doses to prevent river blindness and other diseases in Africa and other places where parasites are common. A group of 10 doctors who call themselves the Front Line Covid-19 Critical Care Alliance have said ivermectin is "one of the safest, low-cost, and widely available drugs in the history of medicine."

NEWSLETTER SIGN-UP

Opinion: Morning Editorial Report

All the day's Opinion headlines.

PREVIEW SUBSCRIBE

Some 70 clinical trials are evaluating the use of ivermectin for treating Covid-19. The statistically significant evidence suggests that it is safe and works for both treating and preventing the disease.

Advertisement - Scroll to Continue

In 115 patients with Covid-19 who received a single dose of ivermectin, none developed pneumonia or cardiovascular complications, while 11.4% of those in the control group did. Fewer ivermectin patients developed respiratory distress (2.6% vs. 15.8%); fewer required oxygen (9.6% vs. 45.9%); fewer required antibiotics (15.7% vs. 60.2%); and fewer entered intensive care (0.1% vs. 8.3%). Ivermectin-treated patients tested negative faster, in four days instead of 15, and stayed in the hospital nine days on average instead of 15. Ivermectin patients experienced 13.3% mortality compared with 24.5% in the control group.

Moreover, the drug can help prevent Covid-19. One 2020 article in Biochemical and Biophysical Research Communications looked at what happened after the drug was given to family members of confirmed Covid-19 patients. Less than 8% became infected, versus 58.4% of those untreated.

Despite the FDA's claims, ivermectin is safe at approved doses. Out of four billion doses administered since 1998, there have been only 28 cases of serious neurological adverse events, according to an article published this year in the American Journal of Therapeutics. The same study found that ivermectin has been used safely in pregnant women, children and infants.

If the FDA were driven by science and evidence, it would give an emergency-use authorization for ivermectin for Covid-19. Instead, the FDA asserts without evidence that ivermectin is dangerous.

At the bottom of the FDA's warning against ivermectin is this statement: "Meanwhile, effective ways to limit the spread of COVID-19 continue to be to wear your mask, stay at least 6 feet from others who don't live with you, wash hands frequently, and avoid crowds." Is this based on the kinds of double-blind studies that the FDA requires for drug approvals? No.

Mr. Henderson, a research fellow with the Hoover Institution at Stanford University, was senior health economist with President Reagan's Council of Economic Advisers. Mr. Hooper is president of Objective Insights, a firm that consults with pharmaceutical clients.

Correction

This article has been edited to remove a reference to a study of 200 healthcare workers by Ahmed Elgazzar of Benha University in Egypt. Messrs. Henderson and Hooper relied on a summary of studies published in the American Journal of Therapeutics. They learned after publication that this study has been retracted because of charges of data manipulation.

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

UPCOMING EVENTS

Oct 12 2021 10:30 AM - 3:00 PM EDT WSJ Risk & Compliance Forum

Oct 18 2021 9:00 AM - 5:00 PM EDT WSJ Tech Live

ADD TO CALENDAR

MOST POPULAR NEWS

- Scarlett Johansson Sues Disney Over 'Black Widow' Streaming Release Sunisa Lee Wins the Women's Gymnastics All-Around Gold 'I Need to Call It': Behind Simone Biles's Stunning Olympic Withdrawal Delta Variant and Vaccines: What to Know Real Estate Is Booming in Bozeman, Mont.—or Shall We Say, Boz Angeles

MOST POPULAR OPINION

- Opinion: Why Is the FDA Attacking a Safe, Effective Drug? Opinion: Is Joe Biden Sinking? Opinion: The Federal Reserve's Big Inflation Miss Opinion: Two False Narratives About the Capitol Riot Opinion: The American Jobs Plan Is a Call to Arms for the GOP

RECOMMENDED VIDEOS

- Video: Explosion at German Chemical Plant Sends Plumes of Smoke Into the Sky Jan. 6 Commission, Prosecutions Could Yield Revelations Despite Partisanship India Floods, Landslides Kill More Than 100 What to Know When Picking a Stock Boeing Dreamliner: A Timeline of the 787's Recent Production Problems

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue

Advertisement - Scroll to Continue